feel well live long make difference day corporate responsibility report maikminpgr oav idnigff ehreeanlcthe eevveerryy ddaay contents cover introduction chairman community investment sri lankan mother child wait chief executive officer business ethic integrity line receive gsk albendazole gsk environment health safety medication global manage corporate responsibility value people programme eliminate lymphatic summary indicator research development filariasis lf story contribution society discussion medicine develop world web reference highlight humanitarian product community investment donation value value million million million combivir supply develop albendazole treatment donate country preferential price fight lymphatic filariasis notforprofit price combivir reduce corporate responsibility principle formally adopt greenhouse gas emission unit sale manager certify compliance code conducttoday corporate responsibility particular resonance pharmaceutical sector business create medicine treat prevent disease society need value time healthcare financing way deliver provoke debate report deal important issue embark programme continual business explain improvement environment health safety possible performance tenyear plan excellence include performance measure include detailed measure target area progress way meeting target year significant achievement year include programme develop world introduce new marketing code example lymphatic filariasis lf elephantiasis back high level board debilitate disease affect million head business division people medicine albendazole helps prevent effort reinforce code leave transmission lf partnership doubt acceptable world health organization donate seriousness contravene code million treatment target eliminate lf time expect gsk commit achieve donate billion treatment worth performance integrity profit billion pharmaceutical principle sustainable provide clarity industry large donation programme mean adopt new corporate responsibility principle expect continue research development gsk consider apply treatment disease develop work world effort complement access initiative particularly aids africa look forward report progress develop country preferential year pricing agreement establish real progress address disease suffer poor country occur responsibility share sector global society government international agency sir christopher hogg jp garni company gsk chairman chief executive officer corporate responsibility report gsk glaxosmithkline gsk lead researchbase pharmaceutical company prescription medicine vaccine overthecounter medicine oral care nutritional healthcare product global company headquarter uk major operation business account seven cent world pharmaceutical market particularly strong position therapeutic area include respiratory antiviral central nervous system diabete vaccine company statistic financial profile operation sale country trading profit business performance manufacturing facility rd spend rd facility sale employment pharmaceutical total employee europe pharmaceutical manufacturing sale marketing international rd pharmaceutical administration consumer healthcare report report summarise gsk corporate responsibility activity performance information issue cover report available website wwwgskcom corporate responsibility report manage corporate responsibility gsk formally adopt corporate responsibility principle clearly identify key corporate responsibility cr issue provide guidance employee standard company commit corporate responsibility principle standard ethical mission business improve quality conduct human life enable people feel well live expect employee meet high ethical long focus need patient achieve standard aspect business mission product activity conduct activity honesty integrity adhere cr principle enhance contribution society sustain comply applicable law regulation economic performance operate environmentally responsible manner employment practice leadership advocacy research innovation treat employee respect establish challenging standard undertake research innovate dignity encourage diversity ensure fair corporate responsibility appropriate explore apply new technology treatment phase employment complexity specific need business constructively engage stakeholder provide safe healthy working build external guideline experience concern arise environment support employee perform share good practice seek influence ensure product subject potential responsibility remain competitive order rigorous scientific evaluation testing performance reputation business sustain business safety effectiveness quality comply exceed regulation legal standard applicable research development product human right community investment product customer commit uphold un positive contribution promote product line high universal declaration human right community operate ethical medical scientific standard oecd guideline mnes core labour invest health education programme comply applicable law regulation standard set international labour partnership aim bring sustainable organisation expect standard improvement underserve people supplier contractor business develop develop world partner work gsk behalf access medicine engagement care stakeholder environment continue research develop medicine treat disease develop want understand concern operate environmentally responsible world find sustainable way improve interest corporate responsibility manner systematic management access medicine disadvantage people issue engage range environmental impact measurement seek partnership support activity stakeholder communicate openly performance set challenging performance address cr issue target improve efficiency way aim meet need different activity minimise material energy use group allow pursue legitimate waste generate aim find opportunity business goal use renewable material recycle waste corporate responsibility report pharmaceutical sector need demonstrate responsibility wide range issue gsk show aware key cr issue clear structure manage gsk management keep cr committee inform activity responsive committee suggestion donald mchenry chairman corporate responsibility committee corporate responsibility committee gsk corporate responsibility committee consist nonexecutive director report board committee meet time review activity number area include donation community investment consumer advertising corporate responsibility management report political activity programme disease develop world donald mchenry dr michle barzach sir christopher hogg dr lucy shapiro chairman corporate dr barzach member sir christopher nonexecutive dr shapiro ludwig professor responsibility committee mr international cooperation high chairman reuters group plc cancer research department mchenry distinguish professor council chairman board member supervisory board developmental biology director practice diplomacy equilibre et population director air liquide sa chairman beckman centre molecular school foreign service board project hope royal national theatre genetic medicine stanford georgetown university international consultant health nonexecutive chairman university school medicine president irc group llc strategy french gsk minister health family management corporate responsibility believe corporate responsibility effectively manage business operation expert cr issue employ corporate gsk board responsibility small corporate team committee coordinate policy development ethic integrity report communication socially responsible investor ceo access medicine gsk research innovation corporate executive stakeholder team engagement human right corporate responsibility community strategy report investment employment practice environment product advocacy customer corporate responsibility report key impact area summary indicator medicine develop world main indicator track researrcehs etaor cfihn dto rfeinadtm treenattsm feonr tdsi sfeoar sdeiss eoafse deovfe tlohpe indgev weloorpldin g pwroovrilddin pgr ovvaicdciinnge performance range corporate responsibility issue mveadccicinineess afnodr tmhee dpiocionreess tf ocro uthnet rpieoso aretst preferceonutinatl rpiersic aet p referential price pagepage issue community investment medicine develop world philanthropic work primarily supply arrangement preferentially price antiretroviral arvs focus health education number country supply preferentially price arvs number combivir tablet ship number albendazole tablet donate number country supply albendazole community investment total community investment expenditure total value product donation include albendazole business ethic integrity total value product donate gsk patient standard behaviour require assistance program employee step business ethic integrity taking ensure achieve number employee complete certification code conduct environment number contract manufacturer audit environment health safety energy consumption million gigajoule resource efficiently water consumption million cubic metre minimise impact product ozone depletion potential meter dose inhaler operation environment tonne cfc equivalent protect employee ozone depletion potential production tonne cfc equivalent contractor workplace ozone depletion potential refrigeration ancillary use tonne cfc equivalent volatile organic compound emission thousand tonne global warming potential energy source thousand tonne co equivalent value people hazardous waste dispose thousand tonne commitment diversity equal health safety opportunity create work lose time injury illness rate case hour work environment talent lose time injury illness rate contractor work site people thrive case hour work value people woman management grade research development ethnic diversity people colour conduct publication research development clinical trial need animal gsk animal research facility accredit association testing safeguard assessment accreditation laboratory animal care treatment assess benefit develop performance indicator continue account view stakeholder corporate responsibility report e v gsk play important role society research new treatment vaccine product donation preferential pricing develop country support patient afford medicine example contribute day american access medicine free charge subsidise rate people insurance able afford medicine million invest scientific medical research day society rely pharmaceutical industry discover develop medicine future corporate responsibility report e day million gsk vaccine distribute worldwide prevent disease help improve public health albendazole preventative treatment donate people develop country albendazole help prevent transmission lymphatic filariasis debilitate disease affect million people develop country tablet combivir ship treat hivaids patient develop country make antiretroviral affordable sustainable preferential pricing help tackle global hivaids epidemic corporate responsibility report contributio business develop marketing medicine vaccine improve health quality life million people world commercial organisation need profit fund future investment pay dividend shareholder believe government develop world patient assistance program intergovernmental body primarily people develop world continue gsk patient assistance program pap responsible meeting world suffer die preventable treatable give lowincome uninsured patient access medicine need health challenge include disease access afford develop world medicine need adequate healthcare replace function government facility gsk make major contribution commitment access cover cancer charity support research treatment vaccine treatment medicine available programme bridge important way disease common develop access significant role play country provide product preferential price invest community health people receive free pharmaceutical research education programme describe gsk medicine programme total commitment pap develop country medicine detail million eligibility criterion grant benefit advance programme generous develop world mean long risk offer pharmaceutical industry develop country section disease polio tb society sufficient access medicine patient eligibility determine major threat century ago phone enrol patient particular concern illness receive prescription medicine immediately people cover public private health treatment treatment local pharmacy addition patient improve insurance help patient help find source fund insurance coverage gain access medicaid aids drug assistance program prescription medicine number initiative state children health insurance program discover develop new medicine state elderly drug assistance program prevent treat disease expensive average cost million take gsk pharmaceutical company company promote pap offer card provide saving medicine website tell patient support year low income senior citizen disable people available help increase takeup orange card available group gsk invest provide saving gsk billion research prescription medicine end patient enrol programme development gsk join enable employ pharmaceutical company offer lead scientist provide rx card low income patient eligible medicare technology need able afford prescription medicine push forward frontier rx provide discount different medicine medical science operate patient assistance program society rely pharmaceutical company provide medicine worth investment fund research million provide cost funding resource industry integral minimal cost patient development new medicine medical insurance go medicine corporate responsibility report n society important job help people baltimore county medical insurance gsk programme make easy help process quick hope gsk medicine prescription patient pay month supply medicine matter drug require invaluable uninsured patient choose medicine food literally save life wendy freeman case manager baltimore county health department maryland corporate responsibility report medicine f develop lack access basic medication healthcare facility lead healthcare crisis develop world gsk commit play lead role address crisis gsk response crisis element progress half largely potential preferential pricing offer antiretroviral follow improvement manufacturing purchaser delay placement order arvs hivaid antimalarial economy scale cut notforprofit anticipation new funding source notforprofit basis vaccine significant price arvs april october available early discount poor country combivir available day increase shipment year research development investment compare december search new treatment vaccine difficult quantify number patient disease develop world public sector agreement treat result programme community investment activity supply arvs country include control healthcare provision partnership support improve health arv supply agreement employer sub study september unle underserved community saharan africa accelerate access initiative aai indicate subsaharan africa number patient preferential pricing ship million treat arvs supply company gsk arvs antimalarial medicine preferentially price combivir tablet aai double year available public sector notfor develop country small proportion profit price world poor shipment figure exclude product patient need treatment substantial country include subsaharan africa sell notforprofit price west africa coverage require funding pay well notforprofit price arvs available illegally divert europe amount healthcare infrastructure ensure safe private employer subsaharan africa quarter notforprofit combivir sale delivery medicine patient provide care treatment uninsured staff year decline shipment second project fully fund global fund fight aid tb malaria eligible supply arrangement type customer notforprofit price available country negotiate preferential price middleincome country casebycase basis notforprofit price set cover manufacture distribution cost ensure sustain supply product long patient need world health organization set target treat million hiv positive people develop country arvs commit make strong contribution achievement goal q q q q q q q q q q q q q employer public hospital ngo govt non aai aai corporate responsibility report medicine develop world ope world extend voluntary licence pilot project underway explore world similar group exist vaccine grant generic manufacturer aspen opportunity extend preferential pricing organisation base belgium pharmacare include sale private wide range medicine sector agreement aspen run partnership ngo zambia malawi progress manufacture sell key gsk arvs uganda tanzania nigeria early observation february launch new meningitis subsaharan africa public suggest great medical need vaccine africa mencevaxacw develop private sector discussion underway basic essential medicine furthermore available african second generic manufacturer similar medicine supply low price country preferential price euro licence gsk arvs africa access treatment significantly increase dose adequate healthcare infrastructure product diversion like see deny phase ii clinical trial malaria vaccine treatment patient develop country international community good child begin mozambique partnership undermine preferential price agreement progress support access medicine malaria vaccine initiative help minimise diversion introduce special initiative particular welcome start phase iii clinical trial latin america access pack differentiate preferentially price funding initiative global fund rotavirus vaccine protection product able supply countrie emergency plan aid relief major cause diarrhoea dehydration combivirin special pack g action plan health result diarrhoea lack clean recognise importance preferential pricing water supply cause death half similar effort underway secure prevent product diversion million child year develop country widespread regulatory approval trizivirand need epivirtablet pack retrovirand epivir human clinical trial hiv vaccine continue solution pack different research development year research colour arv tablet currently cure potential hiv vaccine anticipate take disease affect develop country tb vaccine phase development early apply register number exist treatment arvs eus antidiversion regulation effective drug resistance investment october sign technology transfer design prevent illegal product diversion rd new treatment vaccine supply licence agreement brazilian europe vital publicprivate partnership ppp government production measle essential fund research mump rubella vaccine enable commercially viable market potential million child brazil product work vaccinate year government un agencies global funding body area july lapdap antimalarial treatment develop gsk ppp receive believe currently company approval uk regulatory agency research new vaccine treatment expand research agreement s priority disease medicine malaria venture develop world hivaid tb malaria include development cda combination clinical development programme lapdapand artesunateas new class product relevance develop antimalarial drug discovery world seven aim specifically disease disproportionately affect develop phase ii clinical trial sitamaquine new oral country table number pre treatment visceral leishmaniasis complete clinical project underway kenya india demonstrate promise efficacy clinical study plan q q q q q q q q q q q q team researcher uk tre canto discontinue development spain establish specifically focus oxibendazole intestinal worm treatment research disease develop offer advantage exist medicine corporate responsibility report snoillim deppihs stelbat shipment combivir tablet exclude divert product preferentially priceddevelopment pipeline end disease relevant develop world pre focus clinical phase phase ii phase iii market activity hiv nonnrti ziagenepivir epivir retrovir ccr antagonist ziagen combivir aspartyl protease inhibitor agenerase trizivir nrti lexivatelzir vaccine hiv hepatitis e rotarix rotavirus havrix hepatitis engerix b hepatitis b dengue fever malaria streptorix twinrix hep b infanrix diptheria tetanus n meningitidi spneumoniae paediatric acellular pertussis cervarix hpv tritanrix diptheria tetanus polio sabin polio cell pertussis priorix measle mump typherix typhoid rubella hiberix haemophilus mencevax acw meningitis influenzae type b malaria cda chlorproguanil tafenoquine malarone halfan dapsone artesunate lapdap tb sitamaquine zentel deworme agent visceral leishmaniasis pentostam visceral leishmaniasis submit approval detailed information product pipeline find annual report tenyear partnership programme community investment aids africa kenwa believe action tb complete research develop country positive action workshop write effective programme improve understanding manage large community investment fundraising proposal helped secure grant tb help inhouse development programme develop country include global fund fight aid target effective treatment donation medicine financial tb malaria disease practical support public health initiative education programme large gsk france foundation gskendowe support clinical trial develop programme include tackle major charitable foundation support range country assess use arvs resource disease lymphatic filariasis lf commonly programme improve access healthcare poor setting seven new study begin sub know elephantiasis hivaids malaria hivpositive people africa particularly saharan africa bring total woman child year region include dart study elimination lymphatic filariasis lf foundation provide million large adult hiv treatment study africa lf affect million people support programme african country involve patient uganda develop country world zimbabwe supply drug lead cause permanent disability progress study prevention mothertochild hiv billion people onefifth world positive action support programme transmission involve patient population risk lf infection gsk partnership organisation develop country albendazole prevent transmission lf country gsk france take medicine foundation support initiative pledge hiv treatment regimen complex founding partner s global program renew commitment year require patient combination eliminate lf expect donate billion gsk grant million year different tablet different time treatment worth estimate support work hivaid clinic day increase risk patient miss billion value wholesale price malawi uganda dose take medicine wrong time reduce effectiveness progress gsk african malaria partnership treatment lead drug resistance gsk donate million treatment partnership provide million look way simplify treatment regimen albendazole country donate kickstart funding year support seek regulatory approval million preventative treatment malaria education programme initiative europe new fixeddose combination million people programme design improve prevention epivir ziagen currently expect eventually reach billion people management malaria seven african country separate tablet recommend treatment example support help freedom regimen approve onetablet programme hivaid hunger develop malaria education module combination take day year hivaid programme positive credit education programme provide replace tablet currently take action work community level package financial service health twice day support hiv care education prevention business education help poor woman fight initiative positive action partnership chronic hunger illness poverty october fda approval secure organisation centre african family lexiva new hiv protease inhibitor currently study cafs tackle issue stigma progress protease inhibitor offer flexible dose discrimination significant barrier healthcare contribute grant partner food water restriction hope community affect hivaid freedom hunger amref plan start launch lexiva know telzir international donate plan develop country cafs provide training course community international assist relief operation organisation work people affect increase malaria case sudan follow december gsk recognise hiv train key worker severe flooding leadership alleviate tropical infectious disease ngo build run effective organisation improve global health american help people affect hiv wellplaced society tropical medicine hygiene support powerful impact example kenyan network woman corporate responsibility report lapdap help meet urgent need affordable antimalarial treatment use africa show work case sp standard treatment fail professor peter winstanley university liverpool lapdap new antimalarial sub saharan africa malaria affect million people year urgent need new affordable treatment combat disease deal problem resistance exist treatment new antimalarial treatment lapdap launch design tackle deadly disease develop specifically use subsaharan africa malaria kill million people year majority child initiative bring gsk drug development researcher scientist africa lead uk medical schools university liverpool london school hygiene tropical medicine gsk uk government department international development jointly fund development project lapdap approve use uk medicine healthcare product regulatory agency line good medical practice gsk conduct post marketing study africa confirm longterm safety treatment gsk register lapdap subsaharan africa available national malaria control programme preferential price treatment register african country develop cda new lapdap plus artesunate combination therapy medicine malaria venture corporate responsibility report community investment children health fund referral management initiative homeless disadvantaged child especially vulnerable illness likely suffer acute chronic illness asthma receive vaccination despite need specialist care difficult family hospital appointment million child access healthcare need lack transport doctor disadvantage community cultural language institutional barrier transient lifestyle mean lose contact doctor year gsk provide million children health fund set run referral management initiative rmi help child refer specialist attend appointment receive care need rmi remind family appointment phone mail provide doortodoor transport clinic help communication include provide translation service necessary gsk sole funder rmi provide additional funding help extend programme develop guidance introduce similar initiative nationwide rmi dramatically increase number child medical specialist refer approximately child programme get specialist care need compare initiative begin children health fund partnership gsk responsible positively transform life ten thousand medically underserved child need specialist care irwin redlener president children health fund corporate responsibility report community investment concentrate community investment improve health education underserve vulnerable community worldwide contribution mainly donation medicine financial practical support material laboratory office equipment identify programme support medicine reach iraq basis need potential conflict begin provide impact commercial business medicine follow earthquake india flood nicaragua global community investment charitable donation value million humanitarian donation higher equivalent pretax profit statutory previous year reflect variability result include million patient supply demand donation year year assistance program medicine donation need humanitarian relief depend low income group million event conflict natural disaster humanitarian product donation supply product gsk available include management expense million donation vary excess stock cost run community investment available offer charity programme place clearly identify community need addition agreement community investment programme number charity focus major public health initiative hiv select product gsk stock fulfil plan malaria lymphatic filariasis relief programme emergency aid humanitarian aid support community world employee involvement support community world programme support community need humanitarian aid world example aftermath humanitarian disaster vital prevent spread infectious disease antibiotic play essential role uk gsk impact award recognise reward donate antibiotic support relief effort work small voluntary organisation country affect natural disaster war dedicated improve community healthcare donation ngo partner award include americare interchurch medical organisation deal issue diverse assistance map international project hope sexual abuse mental health problem day organisation request gsk medicine care elderly new life counselling service accord need enable receive award work counselling respond quickly emergency family affect unrest northern ireland medicine warehouse donate medicine worth delight million value wholesale price excellent work carry new life support relief effort country gsk counselling service recognise gsk impact award method give include patient assistance program honour national level prestigious award source product great pride concern cash des brown mp minister responsibility health kind social services public safety northern ireland product donation value wholesale acquisition corporate responsibility report cost relate price gsk charge wholesaler warehouse chain retail pricethe government investment gsk build basic healthcare commit excellence science infrastructure way education delight ensure vulnerable gsk major sciencebased people suffer company imperial college illhealth infant mortality support important initiative greta beresford safe childbirth coordinator healthprom rt hon tony blair mp british prime minister speaking launch inspire june gsk help improve school student young people hiv face social stigma north america interest achievement science increase discrimination make hard gsk impact award recognise notforprofit number science teacher continue live normal life gsk support organisation philadelphia help inspire innovative scheme postdocs seypa programme combats social improve healthcare award help research education scheme gsk exclusion european country community organisation raise fund provide million year year grant youthle focus recruit new volunteer support great scheme develop partnership group young people find solution number people award imperial college london specialist problem face include develop organisation deal school trust inspire place postdoctoral training help organisation provide well issue child abuse breast cancer researcher specialist science school support young people affect hiv sexual reproductive health assist science teaching study teaching qualification provide azerbaijan home refugee gsk support children health fund sponsorship help school gain specialist provide year safe enable improve access healthcare science status childbirth programme improve healthcare homeless child pregnant woman reduce infant mortality year support medical research programme run partnership gsk major supporter university charity work aim benefit charity healthprom azerbaijan ministry north carolina innovative travel science people future give health use qualified doctor nurse laboratory destiny laboratory visit research project run tommys train local healthcare provider underserve secondary school reach baby charity international spinal research midwife develop healthcare training student programme trust epilepsy research foundation material local gsk business help encourage woman minority student national osteoporosis society vaccinate refugee child measle pursue science career mump rubella gsk positive action programme funding science summer free science ukbase ngo call develop zippys friend school initiative run education programme aim inspire lowcost health education resource uk partnership child teach young child pursue science career student learn prison community health advice support child skill cope adversity fun handson experiment relate science education chase programme design family change bereavement bullying day life child raise awareness sexual health issue gsk support helped extend participate programme library prevent spread hiv tb hepatitis project denmark lithuania goa philadelphia area pilot uk prison india uk hope programme adapt use resourcepoor setting europe child cope cancer lifethreatening illness encourage rediscover childhood barretstown ireland lenvol camp france donate partnership support programme gsk employee give time help run event child barretstown provide essential business expertise training barretstown team forge gsk share skill resource great example company know firm recognise value partner charity merely donate money james hill chairman barretstown corporate responsibility report million people treat lymphatic filariasis day medicine donate gsk sri lankan ministry health mobilise healthcare worker volunteer treat half population risk lf day million people sri lanka halfway year treatment plan country continent work eliminate lf forever international china working partnership rural nursing excellence programme british australian red cross reach young thailand help nurse qualify people drug user prevent spread start provide support hiv young people take hospital clinic gsk donate training programme reach programme provide train young people far woman lack nurse major barrier improve healthcare rural area employee involvement programme encourage skill gsk employee volunteer time benefit village expertise worthy cause local community include participate gsk support awardwinne personal hygiene day care notforprofit organisation sanitation education phase programme run mentor school child help turn simple partnership amref plan international uk science engineering ambassador idea promote children reduce diarrhoearelate disease school scheme partnership educational child simple handwash discovery health international programme expand fourth country zambia ministry education gsk match donation programme not usaid roll school million gsk employee wish well peru ministry health retiree match gift program addition million donate gsk partner help africa child employee united way campaign healthy future integrate match gsk give total million chris bale director partnership child management childhood illness imci strategy gsk investment volunteer excellence develop unicef imci aim programme make donation register reduce death treatable preventable charity gsk employee disease improve skill health worker partner volunteer help family well care sick child gsk provide fund uk make difference initiative technical expertise initiative provide financial support charity expand south africa ethiopia gsk employee involve voluntary work namibia nigeria gsk product donation humanitarian relief effort allow save life serve catalyst building sustainable health programme develop world veronica arroyave director corporate relation map international corporate responsibility report gsk commit ensure business practice meet high standard employee behave ethically honestly compete fairly avoid conflict interest section business ensure compliance department finance human resource standard particular relate manager expect lead example legal compliance internal audit work marketing team comply code conduct monitor compliance policy gsk policy support staff applicable law marketing sale code conduct introduce annual practice monitor internal audit gsk code conduct set standard certification process manager department audits business expect employee meet require vicepresident level ensure fully investigate suspect breach employee behave honestly line understand responsibility policy appropriate disciplinary action company policy law avoid extended certification include midlevel warrant conflict interest report violation management uk code unethical behaviour manager participate certification gsk provide input compliance program guidance pharmaceutical help employee understand code employee concern raise manufacturer develop health constitute acceptable unacceptable corporate compliance officer human service office inspector general behaviour practice issue business unit compliance officer guidance publish april employee guide business conduct code confidential po box helpline design help pharmaceutical company guide available company stakeholder contact customer response establish effective compliance programme intranet centre redirect call appropriate senior prevent unlawful unethical conduct management benchmarking programme guideline business ethic integrity corporate responsibility report business ethic integrity marketing practice regional code introduce advertising sell medicine company designate area subject regulation set government champion coordinate distribution medicine agency gsk internal policy code train staff code translate encompass build requirement local language sale marketing employee receive copy product market sale representative regularly meet doctor training workshop electronic medium pharmacist inform ensure staff understand code medicine approve use constitute acceptable promotional activity performance integrity market product directly consumer employee involve sale marketing permit receive regular training product aspect absolutely non provide accurate information doctor negotiable adherence specific policy guidance sale marketing employee national level ensure new code major way marketing accurate base valid scientific evidence complie law commit russell greig president pharmaceuticals international gsk gsk companywide policy conduct business pharmaceutical marketing promotion activity apply employee agent set integrity mean comply commitment promotional practice fully letter ethical responsible principled patientcentred prohibit bribery law spirit inducement doctor prescribe medicine objective look loophole creative interpretation law detailed guidance provide international regional industry code shall benchmark practice adhere include simply compare international federation pharmaceutical manufacturer association ifpma code competitor satisfy pharmaceutical marketing practice good bad addition gsk develop keep review regional marketing code andrew witty president pharmaceuticals europe gsk ensure difference market structure national healthcare system legal framework appropriately reflect enhance compliance culture sale regular high road newsletter audio programme marketing help reinforce key point training pharmaceutical sale marketing division employee date new development introduce programme business company establish advisory board integrity key requirement initiative call sale manager business provide high road ethic legal compliance aim feedback new initiative help ensure compliance ensure employee understand comply sale programme practical userfriendly marketing policy compliance department confidential gsk education essential element comprehensive integrity helpline publicise employee paper online manual develop know question contain sale marketing policy guideline concern sale employee facility ask employee qas key subject available question sale marketing policy employee new exist sale marketing employee attend compliance training new computerbased training monitor behaviour important element module develop ensure compliance fulltime project team look employee complete compliance training detail monitoring process sale video perform integrity support training marketing introduce improvement include perspective gsk sale people necessary audits conduct key compliance area past year corporate responsibility report environme health environment health safety ehs issue manage integrate system ensure issue risk identify training provide target set audits conduct ehs standard apply operation develop tenyear strategic plan plan excellence environment important environmental issue include systematic plan improve air quality volatile organic compound vocs environment health safety performance solvent manufacturing contribute ehs plan excellence longterm goal formation smog drive manufacturing impact switch renewable resource climate burn fossil fuel energy operation increasingly compatible produce carbon dioxide contribute principle sustainable development global warming climate change identify appropriate parameter ozone depletion product track progress main impact manufacturing process use cfcs gas follow formation gsk establish damage ozone layer release baseline value parameter atmosphere set improvement target achieve end chart waste raw material pharmaceutical production process important element approach hazardous require special disposal method consultation people outside gsk expert community neighbour water waste water discharge affect site routinely manufacture site require treatment level aim stakeholder release access information need opportunity tell think want improve corporate responsibility report not environment health safety safety technological change improve material recovery new technology help improve environmental performance gsk manufacturing site ulverston uk introduce new membrane filtration system reduce hazardous waste tonne emission voc tonne annum new system save site million year ulverston large primary manufacturing plant staff acre site situate near lake district area natural beauty ecological importance plant make active ingredient antibiotic acetone voc solvent manufacturing axetil oral antibiotic spray dry process ensure medicine absorb efficiently stomach gut patient bloodstream acetone wash equipment process antibiotic residue acetone valuable need recover disposal acetone previously remote area site system inefficient lot product waste acetone highly flammable pumping site create potential health safety risk site introduce new membrane filtration system separate antibiotic residue acetone allow concentrated efficient recovery result instal new equipment overall process efficient antibiotic recover waste filtration system instal production building reduce solvent transfer site health safety risk site gsk ceo ehs excellence award work implement new system corporate responsibility report progress emission use inhaler cause lose injury time performance relate resource waste manufacturing result ozone disposal climate change air quality deplete potential overall improve target thermalchemical catch inonbetween percentage reduction achieve health safety motor vehicle accident show chart health safety employee overexertionsstrain contractor high priority gsk risk slipstripsfall particularly good progress hazard associate product strike againststruck target area compare operation systematically assess include contact sharps animal figure year set target measure take protect employee insect electricfireexplosion foreign measure normalise sale come contact hazard bodiesobject workplace violence energy consumption associate global warming potential water track number case injury illness consumption ozone depletion result time work set potential production challenge target reduce ozone depletion potential ancillary source year cut injury hazardous waste dispose illness rate reduce cfc propellant meter dose monitor cause incident inhaler mdi use ozone depleting assess learn avoid similar substance refrigeration patient use injury main cause injury slip mdi propellant release trip fall strain overexertion motor atmosphere large source cfc vehicle accident deeply regret emission amount metric tonne workrelate fatality total release gsk employee die drive factory manufacture mdi second accident mesothelioma significant source refrigeration asbestos exposure addition small replacement mdi cfc contractor die forklift truck accident propellant alternative technology cut progress target lose time injury illness rate energy consumption water consumption odp refrigeration ancillary cfc emission odp production cfc equivalent emission volatile organic compound emission global warming potential energy source hazardous waste dispose target lose time injury illness rate annual target improvement baseline environmental measure normalise sale odp ozone depletion potential global warming potential measure co equivalent explanation ehs data ehs report website wwwgskcom ehs datum verify corporate responsibility report value value people people gsk employ people country get good people vital success business key source competitive advantage report twothird gsk employee work embed gsk spirit culture participate individual appraisal process operation worldwide performance development planning pdp development diversity initiative help employee set objective reward introduce human right standard strong performance helps identify procurement process training need develop career pdp process employee gsk spirit manager assess set value quality expect implement gsk spirit work employee embrace work significant impact bonus principle payment award eligible employee performance integrity entrepreneurial spirit use global survey manager focus innovation help analyse effectively build sense urgency gsk spirit year report passion achievement result generally positive work take place get culture right address area identify development aim build culture people progress measure clear company expectation survey take place instinctively right thing operation work employee diversity ensure understand adopt principle gsk commit employ diverse gsk spirit approach tailor workforce individual employee reflect local circumstance event include gsk benefit workplace talented workshop team meeting presentation people thrive diversity award example gsk nigeria background culture outlook help well costume storyteller introduce spirit understand need patient customer employee argentina employee worldwide aim create inclusive work attend halfday culture awareness workshop environment free discrimination ground race ethnicity gender religion sexual leadership development programme orientation disability age design encourage employee apply gsk spirit programme available hold diversity multicultural manager globally level year marketing award philadelphia people attend leadership edge global award annually programme senior manager set demonstrate impact diversity attend leadershipgsk programme improve business performance middle manager programme design share good practice company help manager achieve performance increase insight differ work style strength motivation corporate responsibility report current diversity initiative include woman human right leadership programme support compliance human right requirement career development additionally include criterion hold woman science day uk select supplier introduce attract female science graduate bind clause procurement contract industry undertake review require supplier meet standard uk improve work human right environment access facility website disable employee potential begin incorporate human right employee visitor conclude clause central contract template use early new supplier process complete add clause widen scope employee contract template local operation network new group sale staff delaware valley broad risk human right issue vary spread exist network activity include world appropriate contact career development programme asian major exist supplier assess african american hispanic gay lesbian meet standard key supplier employee ask confirm write comply requirement introduce global management population exist contract review gender implement gsk spirit man woman total contact supplier far consumer healthcare india gain agreement standard date country diverse india create band b unify spirit culture critical success company decline cooperate band c gsk consumer healthcare business band c follow respond request main product horlick major total consumer brand india business employ people site employee question human right issue corporate executive team vice president senior draw india huge vice president add standard list topic discuss difference background religion director level manager level supplier visit procurement ehs culture different language global audit team commonly speak workplace year see increase site develop initiative bring number woman management position supplier find meet standard gsk spirit life enable employee company work achieve compliance understand relevance indian working conduct regular audits ensure environment support business improve performance wide tool spirit website regularly update game quiz report ethnicity datum employee line requirement terminate apply spirit practice people colour account contract supplier work increase slightly compliance company nabha manufacturing site workforce intend rural punjab area literacy rate low use poster cricket cartoon collect report ethnicity datum uk illustrate spirit principle employee operation motivational film use team meeting ethnicity employee population employee manufacture site encourage involved global total operational excellence campaign demonstrate passion work employee develop jdi concept simple idea improve efficiency people colour effectiveness employee nabha contribute jdi include idea improve health safety reduce waste site jdis develop sonepat plant helped save employee reward idea spirit recognition award company focus get culture right help gain recognition india employer declare fifth good employer annual business todayhewitt award partly determined employee feedback corporate responsibility report corporate responsibility report research developme medical research rise ethical concern engage openly constructive debate matter discuss disclosure clinical trial information use animal research evaluate potential new medicine believe healthcare decision clinical trial essential mandatory knowledge relevant step develop new treatment trials information gsk support scientific medical conduct medicine progress make result clinical trial market investigate widely available possible role treatment patient publish clinical trial result peerreviewe study concern safety scientific medical journal conference wellbee trial participant abstract proceeding research future patient healthcare community look source current information clinical trial conduct accordance applicable law regulation work pharmaceutical recognise principle good clinical practice company help clarify industry legally oblige disclose datum approach communication clinical trial clinical trial regulatory authority result develop phrma principle seek approval new product conduct clinical trial communication clinical trial result fully support approval market product give principle apply clinical regulator satisfy product safe study worldwide effective manufacture high consistent quality standard medicine particular reaffirm commitment vaccine approve marketing timely communication meaningful continue provide regulatory authority result control clinical trial market safety information product investigational product approve marketing result positive negative corporate responsibility report research development nd not review discuss manuscript advance management number publication gsk clinical trial clinical investigator conduct gsk heart disease sponsor study submit heart failure condition million people affect half journal conference publication ensure contribute patient die year diagnosis new treatment urgently significantly study write require revise manuscript receive appropriate gsk partner company rise recognition author contributor challenge investigate new use manuscript publish coreg gsk betablocker medicine publish result gather centre treat high blood pressure involve multicentre trial clinical trial result positive individual centre demonstrate add coreg current medication reduce mortality rate publication journal conference patient heart failure slow subject peer review discretion progression disease help journal editor conference organiser patient live long feel well mean gsk guarantee product licence expand clinical trial information publish coreg prescribe doctor way assess additional treatment heart failure option communicate clinical trial information number publication year depend hypertension number trial complete time betablocker number accept publication show effective safe treat heart failure previously believe paper describe result betablocker unsafe heart failure gsk clinical trial publish journal patient conference corporate responsibility report animal research commit rs reduce number animal fluctuate animal research essential understand number animal study refining year year depend factor disease enable evaluate study minimise pain maximise number compound research effectiveness safety new medicine information obtain animal development regulatory requirement give people regulation require replace animal study alternative method introduction new nonanimal research use animal establish new medicine possible technique safe test type vaccine batch produce example replace animal laboratory comply strict national study new research method law guideline code conduct believe important explain need computer modelling test isolate cell regularly inspect government agency animal research open tissue refine procedure employee laboratory work host visit school college use noninvasive technique magnetic behalf follow gsk code practice animal welfare organisation rspca resonance imaging help reduce research team ensure study refine stakeholder laboratory number animal study minimise animal suffer uk visit uk school discuss issue arise animal run award programme encourage obtain additional independent research consult organisation researcher find alternative approach evaluation association assessment nuffield council bioethic use animal gsk rd chairman accreditation laboratory animal care universities federation animal welfare present animal welfare award aaalac international give year employee outstanding accreditation site meet high gsk animal research facility advance implement rs annual standard seven gsk animal europe japan research approximately european gsk laboratory animal welfare prize laboratory uk accredit conduct external contractor external laboratory award good progress work behalf individual group develop new accreditation site continental europe technique enhance ability implement japan plan complete process soon animal use rodent rs year winner norwegian possible remaining include fish amphibian reference centre laboratory animal science rabbit pig dog cat primate alternative approach achieve result number animal gsk broadly year ago despite significant increase rd activity animal research change rd activity compare number animal gsk year rd activity animal ecni egnahc mice rat guinea pig rodent figure normalise level corporate responsibility report discussion engage stakeholder important aspect approach corporate responsibility believe essential listen people view communicate opinion externally interact different people communication employee employee satisfaction survey feedback group interested internal communication particularly important company programme identify business affect product aim inform area well global survey operation employee investor doctor involve company activity seek involved manager patient supplier nongovernmental feedback range initiative world management survey organisation ngo multilateral ensure reach employee right place agency government local company include local level site produce regular community discussion newsletter staff spotlight take place normal course mygsk global intranet site update environment health safety issue business meeting company industry news qa programme specifically review corporate employee question confidential feedback mechanism enable responsibility issue example directly ceo question employee raise concern include socially responsible investor ngo answer month integrity helpline uk news section gsk europe work council european intranet give company position employee consultation forum provide regular important issue link press clipping opportunity employee company gsk management discuss issue spirit internal magazine available employee companywide time year event programme meeting event enable employee level meet ceo senior management discuss progress business raise question feedback corporate responsibility report discussion external stakeholder way interact group depend need type work way interact stakeholder type communication healthcare meet regularly doctor pharmacist tell product discuss issue professional concern conduct market research doctor healthcare example doctor professional feedback pharmacist work medical organisation develop sponsor continue medical education doctor healthcare professional accredit training course asthma care nurse partner healthcare professional design conduct clinical trial research project research result include clinical trial peerreviewe publish medical journal government regular dialogue regulator share information new science technology regulator example support genetic research education programme discuss issue raise genetic potential application healthcare operation liaise regularly environment health safety authority ensure comply fully legal obligation specialist environment health safety employee participate government committee consultation help develop well regulation future sponsor annual conference uk environment agency gsk work green chemistry acknowledge presentation baroness young chief executive agency investor senior manager present final yearend result institutional investor analyst london new york teleconference release quarterly result presentation access website annual general meeting take place london include business presentation shareholder director available answer question senior manager discuss company plan objective governance institutional shareholder include regular meeting participation external investor conference hold rd day december inform investor product development pipeline annual corporate responsibility forum investor hold july senior gsk manager expertise relevant area meet representative investment fund rating agency respond question meet regularly investor discuss corporate responsibility policy performance meeting hold include discussion key impact area address report corporate responsibility report stakeholder type communication nongovernmental discuss approach healthcare need develop country ngos mdecin san organisation frontire freedom hunger oxfam communities work ngo patient group consumer group example smoking cessation asthma vaccination campaign community investment programme work partnership organisation community group meet regularly world evaluate progress meet local community need environment health safety ehs workshop september bring key ngo trade union government representative discuss environmental performance longterm strategy achieve leadership excellence ehs key issue highlight discussion form improvement programme partner number environmental ngo example include sponsor green alliance project raise awareness link environment health funding earthwatch send school teacher conservation project host tour laboratory visit school help improve understand scientific research example use animal operation produce newsletter local community inform work year site host open day gsk site employee undertake project improve environment local area number operation outreach project example horlick plant rajahmundry india recognise ceo ehs excellence award community partnership local project include provision drinking water village experience drought donation desk chair school build bridge improve access school organising deworme programme child scientific community collaborate academic researcher pharmaceutical company research develop new treatment encourage transfer expertise skill work education authority develop sponsor initiative science education school example inspire programme hold regular science policy conference uk partnership government non government stakeholder discuss issue common interest meeting discuss clinical science uk sponsor university research environment health safety issue include project green chemistry ecoefficiency alternative technology reduce environmental impact regularly meet un agency include unaai unicef global fund fight multilateral agency aid tb malaria discuss wide range issue include address hivaid epidemic preferential pricing arrangement create publicprivate partnership rd disease develop world target product donation collaborate ministry health partner global alliance eliminate lf annual whoifpma round table industry discuss partnership opportunity improve global health corporate responsibility report web reference corporate website find wwwgskcom website cite report wwwunorgoverviewrightshtml wwwoecdorgdataoecdpdf wwwiloorgpublicenglishstandardsnormindexhtm httpusgskcomcard wwwtogetherrxcom wwwcommitmenttoaccessgskcom wwwbridgestoaccessgskcom wwwgskcomaboutpricinghtm wwwtheglobalfundorg wwwwhointbypublicationsdocumentsentreatingmillionbypdf wwwstategovpafrlsfshtm wwwmmvorg wwwastmhorgindexhtml wwwgskcomcommunityindexhtm wwwfilariasisorg wwwgskcompositiveactionindexhtm wwwgskfrgskfondmphtml wwwgskcommalariaindexhtm wwwchildrenshealthfundorgrmihtml wwwgskcomcommunityimpactawardsukhtm wwwgskcomcommunityimpactawardsushtm wwwgskcomserserserhtml httpoighhsgovfrauddocscomplianceguidancepharmacymfgnonfrpdf wwwifpmaorgnewsnewsmarketaspx wwwgskcomfinancialrepsehsgskehshtm wwwphrmaorgpublicationspolicypdf wwwgskcomaboutanimalresearchhtm wwwrdsonlineorgukpagesaspitoolbaridipageid wwwaaalacorg corporate responsibility report internet information company available glaxosmithkline corporate website wwwgskcom head office register office glaxosmithkline plc great west road brentford middlesex tw gs uk tel contact company directly corporate responsibility issue csrcontactgskcom report annual review feel well live long review major theme abridge version financial result improve health day annual review annual report feel well live long financial statement improve performance day annual report produce corporate communication glaxosmithkline corporate feel well live long responsibility report design consultancy salterbaxter review corporate responsibility consultancy context commitment society environment photograph courtesy monika graff print uk colourhouse paper making difference production document day pulp harvest sustainable forest sawmill residue forest thinning corporate responsibility report elemental chlorinefree maikminpgr oav idnigff ehreeanlcthe eevveerryy ddaayy product name publication indicate italic trademark glaxosmithkline plc subsidiary associate day world glaxosmithkline company exception levitra try improve people live positive trademark bayer ag nicoderm trademark impact stakeholder year report aventis sa licence emphasise farreache commitment groupwwwgskcom annual review